Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.

ABSTRACT:

Objective

To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19).

Design

Randomised, open label trial.

Setting

Nine hospitals in Brazil, 8 May to 17 July 2020.

Participants

Adults with confirmed covid-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two serum biomarkers (C reactive protein, D dimer, lactate dehydrogenase, or ferritin). The data monitoring committee recommended stopping the trial early, after 129 patients had been enrolled, because of an increased number of deaths at 15 days in the tocilizumab group.

Interventions

Tocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65) versus standard

SUBMITTER: Veiga VC 

PROVIDER: S-EPMC7815251 | biostudies-literature | 2021 Jan

REPOSITORIES: biostudies-literature